Spine stereotactic radiosurgery for metastatic thyroid cancer: A single-institution experience Journal Article


Authors: Boyce-Fappiano, D.; Gjyshi, O.; Pezzi, T. A.; Allen, P. K.; Solimman, M.; Taku, N.; Bernstein, M. B.; Cabanillas, M. E.; Amini, B.; Tatsui, C. E.; Rhines, L. D.; Wang, X. A.; Briere, T. M.; Yeboa, D. N.; Bishop, A. J.; Li, J.; Ghia, A. J.
Article Title: Spine stereotactic radiosurgery for metastatic thyroid cancer: A single-institution experience
Abstract: OBJECTIVE Patients with metastatic thyroid cancer have prolonged survival compared to those with other primary tumors. The spine is the most common site of osseous involvement in cases of metastatic thyroid cancer. As a result, obtaining durable local control (LC) in the spine is crucial. This study aimed to evaluate the efficacy of spine stereotactic radiosurgery (SSRS) in patients with metastatic thyroid cancer. METHODS Information on patients with metastatic thyroid cancer treated with SSRS for spinal metastases was retrospectively evaluated. SSRS was delivered with a simultaneous integrated boost technique using single- or multiple-fraction treatments. LC, defined as stable or reduced disease volume, was evaluated by examining posttreatment MRI, CT, and PET studies. RESULTS A total of 133 lesions were treated in 67 patients. The median follow-up duration was 31 months. Dose regimens for SSRS included 18 Gy in 1 fraction, 27 Gy in 3 fractions, and 30 Gy in 5 fractions. The histology distribution was 36% follicular, 33% papillary, 15% medullary, 13% Hurthle cell, and 3% anaplastic. The 1-, 2-, and 5-year LC rates were 96%, 89%, and 82%, respectively. The median overall survival (OS) was 43 months, with 1-, 2-, and 5-year survival rates of 86%, 74%, and 44%, respectively. There was no correlation between the absolute biological equivalent dose (BED) and OS or LC. Patients with effective LC had a trend toward improved OS when compared to patients who had local failure: 68 versus 28 months (p = 0.07). In terms of toxicity, 5 vertebral compression fractures (2.8%) occurred, and only 1 case (0.6%) of greater than or equal to grade 3 toxicity (esophageal stenosis) was reported. CONCLUSIONS SSRS is a safe and effective treatment option with excellent LC and minimal toxicity for patients with metastatic thyroid cancer. No association with increased radiation dose or BED was found, suggesting that such patients can be effectively treated with reduced dose regimens. © AANS 2020, except where prohibited by US copyright law.
Keywords: adult; cancer survival; aged; treatment failure; major clinical study; overall survival; fatigue; treatment planning; cancer patient; comparative study; nuclear magnetic resonance imaging; follow up; metastasis; pain; radiation; esophagitis; radiotherapy dosage; cohort analysis; radiation injury; medical record review; oncology; retrospective study; histology; protein tyrosine kinase inhibitor; postoperative complication; iodine 131; spinal cord compression; spine; iohexol; therapy effect; thyroid cancer; thyroid carcinoma; stereotactic radiosurgery; cancer control; acute toxicity; thyroid papillary carcinoma; spinal cord disease; metastatic; cone beam computed tomography; gross tumor volume; thyroid follicular carcinoma; thyroid medullary carcinoma; spine stereotactic radiosurgery; anaplastic thyroid carcinoma; thyroid parafollicular cell; myelography; image guided radiotherapy; compression fracture; esophagus stenosis; human; male; female; article; median survival time; ssrs
Journal Title: Journal of Neurosurgery: Spine
Volume: 32
Issue: 6
ISSN: 1547-5654
Publisher: American Association of Neurological Surgeons  
Date Published: 2020-06-01
Start Page: 941
End Page: 949
Language: English
DOI: 10.3171/2019.12.Spine191269
PUBMED: 32059183
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 July 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors